Market News

Opus Point Partners Management Increases Position in Bristol Myers Squibb Co (BMY); Customers Bancorp (CUBI) Stock Price Rose While Bowling Portfolio Management Decreased Holding

Customers Bancorp, Inc. (NYSE:CUBI) Logo

Bowling Portfolio Management Llc decreased its stake in Customers Bancorp Inc (CUBI) by 35.23% based on its latest 2017Q4 regulatory filing with the SEC. Bowling Portfolio Management Llc sold 17,049 shares as the company’s stock rose 9.56% while stock markets declined. The institutional investor held 31,338 shares of the finance company at the end of 2017Q4, valued at $814,000, down from 48,387 at the end of the previous reported quarter. Bowling Portfolio Management Llc who had been investing in Customers Bancorp Inc for a number of months, seems to be less bullish one the $923.21 million market cap company. The stock decreased 0.27% or $0.08 during the last trading session, reaching $29.31. About 150,906 shares traded. Customers Bancorp, Inc. (NYSE:CUBI) has declined 4.56% since May 17, 2017 and is downtrending. It has underperformed by 16.11% the S&P500.

Opus Point Partners Management Llc increased its stake in Bristol Myers Squibb Co (BMY) by 100% based on its latest 2017Q4 regulatory filing with the SEC. Opus Point Partners Management Llc bought 45,000 shares as the company’s stock rose 2.38% while stock markets declined. The institutional investor held 90,000 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $5.52M, up from 45,000 at the end of the previous reported quarter. Opus Point Partners Management Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be bullish on the $85.36B market cap company. The stock decreased 0.17% or $0.09 during the last trading session, reaching $52.21. About 5.42 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has risen 11.37% since May 17, 2017 and is uptrending. It has underperformed by 0.18% the S&P500.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Bizjournals.com which released: “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” on May 01, 2018, also Streetinsider.com with their article: “Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment …” published on May 16, 2018, Seekingalpha.com published: “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” on May 16, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Ziopharm, Trump’s Drug Pricing Plan And The Future Of Expensive Drug Development” with publication date: May 15, 2018.

Investors sentiment decreased to 0.94 in 2017 Q4. Its down 0.09, from 1.03 in 2017Q3. It worsened, as 72 investors sold BMY shares while 526 reduced holdings. 106 funds opened positions while 457 raised stakes. 1.11 billion shares or 0.48% more from 1.11 billion shares in 2017Q3 were reported. 265,681 are owned by Prns Limited. Eastern Bankshares owns 260,966 shares. Bluestein R H & holds 0.01% or 4,620 shares. West Oak Limited Company invested 0.39% in Bristol-Myers Squibb Company (NYSE:BMY). Roffman Miller Incorporated Pa holds 7,903 shares or 0.06% of its portfolio. 554,900 were accumulated by Employees Retirement Sys Of Texas. Blue Capital holds 17,145 shares or 0.61% of its portfolio. 32,790 are held by Longer Invests Inc. 8,128 were accumulated by At Bank. C Worldwide Hldgs A S reported 213,452 shares. United American Incorporated (D B A Uas Asset Management) has invested 0.57% in Bristol-Myers Squibb Company (NYSE:BMY). Argent Trust reported 0.86% stake. Amica Retiree Medical has 0.46% invested in Bristol-Myers Squibb Company (NYSE:BMY). Next Gru has 18,998 shares for 0.5% of their portfolio. Stratos Wealth Ptnrs reported 0.85% stake.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 2 Sell and 13 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 86 analyst reports since July 28, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of BMY in report on Monday, September 18 with “Hold” rating. The rating was maintained by Barclays Capital on Friday, September 9 with “Equal-Weight”. Piper Jaffray maintained the shares of BMY in report on Thursday, July 27 with “Hold” rating. UBS maintained the stock with “Buy” rating in Friday, August 19 report. The stock has “Underweight” rating by Piper Jaffray on Monday, August 24. Cowen & Co maintained Bristol-Myers Squibb Company (NYSE:BMY) on Thursday, October 19 with “Hold” rating. The firm earned “Hold” rating on Wednesday, August 16 by Credit Suisse. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Monday, February 26. On Monday, June 5 the stock rating was maintained by BMO Capital Markets with “Sell”. The rating was upgraded by Jefferies to “Buy” on Monday, December 19.

Opus Point Partners Management Llc, which manages about $115.61 million US Long portfolio, decreased its stake in Juno Therapeutics Inc (NASDAQ:JUNO) by 9,132 shares to 5,588 shares, valued at $255,000 in 2017Q4, according to the filing. It also reduced its holding in United Therapeutics Corp Del (NASDAQ:UTHR) by 2,058 shares in the quarter, leaving it with 2,050 shares, and cut its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY).

Since December 12, 2017, it had 2 buys, and 1 insider sale for $163,963 activity. 5,300 shares were sold by Lynch Thomas J. Jr., worth $335,172 on Tuesday, December 12. Shares for $249,187 were bought by Samuels Theodore R. II.

Since February 5, 2018, it had 0 insider buys, and 4 insider sales for $417,893 activity. Issa Steven sold $350,942 worth of stock.

Investors sentiment decreased to 0.92 in Q4 2017. Its down 0.26, from 1.18 in 2017Q3. It is negative, as 16 investors sold CUBI shares while 61 reduced holdings. 22 funds opened positions while 49 raised stakes. 23.85 million shares or 7.90% less from 25.90 million shares in 2017Q3 were reported. Stifel Finance, Missouri-based fund reported 105,300 shares. Delphi Mngmt Inc Ma holds 52,597 shares or 0.78% of its portfolio. Howe & Rusling has invested 0% in Customers Bancorp, Inc. (NYSE:CUBI). 231,601 are held by Principal Financial Group. Nuveen Asset Mgmt Llc invested in 0.14% or 823,225 shares. First Tru Advisors Lp has 52,184 shares. Wells Fargo And Com Mn reported 0% of its portfolio in Customers Bancorp, Inc. (NYSE:CUBI). Menta Cap Limited Liability Corp has invested 0.47% in Customers Bancorp, Inc. (NYSE:CUBI). Wellington Management Gp Llp stated it has 28,738 shares. Livforsakringsbolaget Skandia Omsesidigt stated it has 0.02% in Customers Bancorp, Inc. (NYSE:CUBI). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 798 shares. Aqr Capital Management Ltd Liability Corporation holds 0% of its portfolio in Customers Bancorp, Inc. (NYSE:CUBI) for 131,413 shares. Laurion Cap Management LP accumulated 19,932 shares. Utah-based Wasatch Advisors Inc has invested 0.04% in Customers Bancorp, Inc. (NYSE:CUBI). Strs Ohio accumulated 0% or 30,100 shares.

Analysts await Customers Bancorp, Inc. (NYSE:CUBI) to report earnings on July, 25. They expect $0.63 EPS, down 19.23% or $0.15 from last year’s $0.78 per share. CUBI’s profit will be $19.84M for 11.63 P/E if the $0.63 EPS becomes a reality. After $0.64 actual EPS reported by Customers Bancorp, Inc. for the previous quarter, Wall Street now forecasts -1.56% negative EPS growth.

Among 8 analysts covering Customers Bancorp (NYSE:CUBI), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. Customers Bancorp had 29 analyst reports since October 30, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Monday, December 19. The rating was maintained by Maxim Group with “Buy” on Wednesday, February 1. The company was maintained on Friday, October 30 by Maxim Group. The rating was maintained by Maxim Group with “Buy” on Friday, October 20. The stock of Customers Bancorp, Inc. (NYSE:CUBI) earned “Buy” rating by B. Riley & Co on Friday, December 8. The rating was maintained by Keefe Bruyette & Woods on Tuesday, September 20 with “Market Perform”. The rating was maintained by Keefe Bruyette & Woods on Thursday, June 29 with “Hold”. Maxim Group maintained Customers Bancorp, Inc. (NYSE:CUBI) on Tuesday, May 1 with “Buy” rating. FBR Capital maintained it with “Buy” rating and $41.0 target in Wednesday, January 3 report. The firm earned “Buy” rating on Thursday, January 25 by FBR Capital.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *